Key result
Olmesartan medoxomil reversed LV angiotensin II-induced cardiomyocyte hypertrophy, LV dysfunction, and abnormal coronary angiogenesis at 8 and 16 weeks in Spontaneously Diabetic Torii rats.
Why the study?
Does olmesartan medoxomil prevent cardiomyocyte hypertrophy and progression of diabetic cardiomyopathy in Spontaneously Diabetic Torii rats?
Does olmesartan medoxomil prevent cardiomyocyte hypertrophy and progression of diabetic cardiomyopathy in Spontaneously Diabetic Torii rats?
In a rat model of diabetic cardiomyopathy, blocking angiotensin II with olmesartan medoxomil prevents cardiomyocyte hypertrophy and abnormal coronary angiogenesis, suggesting a key role for local ANG II and thrombospondin-1 in disease progression.
Answers are grounded in this paper and cite their sources.
Positive effects in diabetic rat model are hypothesis-generating; leaves open translation to human diabetic cardiomyopathy.
To examine whether and how heart ANG II influences the coordination between cardiomyocyte hypertrophy and coronary angiogenesis and contributes to the pathogenesis of diabetic cardiomyopathy, we used Spontaneously Diabetic Torii (SDT) rats treated without and with olmesartan medoxomil (an ANG II receptor blocker). In SDT rats, left ventricular (LV) ANG II, but not circulating ANG II, increased at 8 and 16 wk after diabetes onset. SDT rats developed LV hypertrophy and diastolic dysfunction at 8 wk, followed by LV systolic dysfunction at 16 wk, without hypertension. The SDT rat LV exhibited cardiomyocyte hypertrophy and increased hypoxia-inducible factor-1α expression at 8 wk and to a greater degree at 16 wk and interstitial fibrosis at 16 wk only. In SDT rats, coronary angiogenesis increased with enhanced capillary proliferation and upregulation of the angiogenic factor VEGF at 8 wk but decreased VEGF with enhanced capillary apoptosis and suppressed capillary proliferation despite the upregulation of VEGF at 16 wk. In SDT rats, the phosphorylation of VEGF receptor-2 increased at 8 wk alone, whereas the expression of the antiangiogenic factor thrombospondin-1 increased at 16 wk alone. All these events, except for hyperglycemia or blood pressure, were reversed by olmesartan medoxomil. These results suggest that LV ANG II in SDT rats at 8 and 16 wk induces cardiomyocyte hypertrophy without affecting hyperglycemia or blood pressure, which promotes and suppresses coronary angiogenesis, respectively, via VEGF and thrombospondin-1 produced from hypertrophied cardiomyocytes under chronic hypoxia. Thrombospondin-1 may play an important role in the progression of diabetic cardiomyopathy in this model.
No takes yet. Share an insight, caveat, or question.
Masuda et al. (2012) studied Diabetic cardiomyopathy. Olmesartan medoxomil vs. Untreated SDT rats was evaluated on Cardiomyocyte hypertrophy, coronary angiogenesis, and LV dysfunction. Olmesartan medoxomil reversed LV angiotensin II-induced cardiomyocyte hypertrophy, LV dysfunction, and abnormal coronary angiogenesis at 8 and 16 weeks in Spontaneously Diabetic Torii rats.
Synapse has enriched 10 related papers. Consider them for comparative context: